Marilyn Ann Huestis (born 1948) is an American toxicologist researching the effects of illicit drugs on the body, brain, and in utero. She was chief of the chemistry and drug metabolism section at the National Institute on Drug Abuse. Meer weergeven Huestis began working in a toxicology lab in 1969 as an undergraduate at a women's college. She married during her senior year, held a variety of jobs and raised a family. Ten years later, Huestis went through a … Meer weergeven Huestis is a toxicologist who studied the effects of illicit drugs on the body, brain, and in utero. After receiving her doctorate in 1992, she founded her own company. In the late … Meer weergeven • Marilyn Huestis publications indexed by Google Scholar Meer weergeven In 2010, Huestis received a doctor honoris causa from the Faculty of Medicine at the University of Helsinki, a school that supported her work on in utero drug exposure. Meer weergeven Web21 aug. 2007 · Marilyn A. Huestis. Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, NIH, 5500 Nathan Shock Drive, Baltimore, …
Oral Fluid Drug Testing: Analytical Approaches, Issues and ...
Web27 mei 2015 · Marilyn A. Huestis, PhD et al. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. Clinical Chemistry, May 2015 DOI: 10.1373/clinchem.2015.238287; Web12 apr. 2024 · Dr. Marilyn Huestis, a former Chief of Chemistry and Drug Metabolism at the National Institute on Drug Abuse, was the first expert featured in the AKA’s presentation. Huestis presented in-depth data that discussed how kratom affects the body from a physiological perspective. churg-strauss症候群 ガイドライン
DART-MS Facilitated Quantification of Cannabinoids in Complex …
WebCookie Durata Descrizione; cookielawinfo-checkbox-analytics: 11 months: This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for … Web25 jan. 2016 · Marilyn A. Huestis The AAPS Journal 18 , 455–464 ( 2016) Cite this article 2413 Accesses 47 Citations Metrics Abstract In 2014, FDU-PB-22 and FUB-PB-22, two novel synthetic cannabinoids, were detected in herbal blends in Japan, Russia, and Germany and were quickly added to their scheduled drugs list. WebDennis J. Sholler, Marilyn A. Huestis, Benjamin Amendolara, Ryan Vandrey, Ziva D. Cooper. The phytocannabinoid Δ 9 -tetrahydrocannabinol (THC) was isolated and synthesized in the 1960s. Since then, two synthetic cannabinoids (SCBs) targeting the cannabinoid 1 (CB1R) and 2 (CB2R) receptors were approved for medical use based on … chururuのときめき夢空間